A service of StreetInsider.com
Ticker Symbol

Most Popular

AAPL 95.18
GOOG 692.36
MSFT 49.78
FB 117.43
BAC 14.36

Recently Added

FANG 84.90
SGY 0.81
WLL 10.29
RMRK 0.00
SYF 31.08

Gaining Speed

WLL 10.29
RMRK 0.00
FANG 84.90
SGY 0.81
BCEI 3.01

ZIOPHARM Oncology (ZIOP) Reports Palifosfamide Hits PFS Events in Phase 3

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that the Phase 3 (PICASSO 3) trial of palifosfamide (ZIO-201) in first-line metastatic soft tissue sarcoma has reached its target number of progression-free survival (PFS) events. PICASSO 3 is an international, randomized, double-blind, placebo-controlled trial whose primary endpoint is PFS....

Read More




Get Alerted When News Hits On This Stock - FREE!